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a  b  s  t  r  a  c  t
Background:  Acute  bronchitis  (AB)  is one  of the  common  diseases.  Tanreqing  injection  (TRQ)  was  widely
used  to treat  patients  with  acute  bronchitis,  and  many  randomized  controlled  trials  have  been conducted
to investigate  its efﬁcacy.
Objective:  The  purpose  of  this  systematic  review  is  to evaluate  the  efﬁcacy  and  safety  of  TRQ  for  AB.
Methods:  Eight  English  and  Chinese  electronic  databases,  up  to October  2014,  were searched  to identify
randomized  controlled  trials on  TRQ for  AB.  Two  reviewers  independently  extracted  data  and  assessed
the  quality  of each  trial by using  Cochrane  handbook.  Meta-analysis  was carried  out  by using Review
Manager  software.
Result: A  total  of  49  trials  with  5131  participants  were  collected.  Data  of three  main  outcomes  were
pooled  and  analyzed  as following:  (1)  effective  rates:  TRQ  versus  antibiotics  (RR  1.12; 95%  CI  1.05, 1.18;
P  =  0.0002);  TRQ plus  antiviral  drugs  versus  antiviral  drugs  (RR:  5.12;  95%  CI 3.03,  8.66; P  < 0.00001);
TRQ  plus  antibiotics  versus  antibiotics  (RR 3.46;  95%  CI  2.59,  4.62;  P <  0.00001);  TRQ versus  antibiotics
plus  antiviral  drugs  (RR 2.03;  95% CI 1.10,  3.74;  P = 0.02);  TRQ  plus  conventional  therapy  versus  conven-
tional  therapy  alone  (RR  1.21;  95%  CI 1.15,  1.27;  P  < 0.00001).  (2) Time  for fever  resolution:  TRQ  plus
antiviral  drugs  versus  antiviral  drugs  (MD:  −1.08;  95%  CI −1.59, −0.57;  P  < 0.00001);  TRQ  plus  antibiotics
versus  antibiotics  (MD  −1.33;  95%  CI  −1.81, −0.86;  P  < 0.00001);  TRQ  versus  antibiotics  plus  antiviral
drugs (MD  −0.88;  95% CI  −1.25, −0.51;  P  < 0.00001);  TRQ  plus  conventional  therapy  versus  conventional
therapy  alone  (MD  −1.06; 95%  CI −1.13,  −0.98;  P < 0.00001).  (3)  Resolution  of  cough:  TRQ  plus  antiviral
drugs  versus  antiviral  drugs  (MD:  −2.09; 95%  CI −3.11,  −1.43;  P < 0.00001);  TRQ  plus  antibiotics  versus
antibiotics  (MD:  −2.65; 95%  CI −2.88, −2.42; P <  0.00001);  TRQ  plus  conventional  therapy  versus  con-
ventional  therapy  alone  (MD  −1.84; 95%  CI −2.85, −0.83; P = 0.0003).  Four  trials  described  the  adverse
drug  reactions  of  TRQ,  while  no  severe  adverse  drug  reactions  reported.
Conclusions:  As a therapy  for AB,  TRQ  has potentially  beneﬁcial  effect  in improving  effective  rates,  reduc-
ing  the time  to resolution  of  fever,  cough,  crackles  and  absorption  of  shadows  on  X-ray.  However,  due  to
the limitations  of methodological  quality  of  the  included  trials,  it is  difﬁcult  to make  a  conclusive  recom-
mendation  about  TRQ  treating  patients  with  AB.  Further  rigorous  clinical  trials  are  warranted  to  evaluate
the  efﬁcacy  and  safety  of TRQ.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Acute bronchitis (AB) is usually caused by viruses and/or bac-
eria. It is an inﬂammation of the large bronchi (medium-size
irways) in the lungs. Cough, with or without phlegm, is a primary
ymptom, lasting less than 3 weeks in contrast to chronic cough.1
ther symptoms including coughing up mucus, malaise, myalgia,
ever, and chest discomfort are not speciﬁc to AB process. There
s a overlap in the symptoms of acute bronchitis and upper respi-
atory infection (URI). Differential diagnosis of the two is almost
mpossible. AB is essentially a diagnosis of exclusion. The only true
iagnostic tool for evaluation of AB is ongoing evaluation of the
atient to see if another disease process reveals itself.2 It is reported
hat most patients with AB are treated with inappropriate or inef-
ective therapies, and many clinical trials have shown that little or
o improvement when antibiotics are prescribed for adults with
B.3,4
Tanreqing injection (TRQ) is extracted from ﬁve kinds of tra-
itional Chinese vedicines (TCM): radix scutellariae, forsythia
uspense, ﬂos lonicerae, bear gall powder, and cornu gorais. Mod-
rn pharmacologic studies found that TRQ can relieve airway
nﬂammation and excessive mucus caused by bacterial (strepto-
occus pneumoniae, haemophilus inﬂuenzae, and pseudomonas
eruginosa) and virus (inﬂuenza virus).5 TRQ is commonly used
o treat acute upper respiratory and early stage of pneumonia in
linical practice in mainland China.6 It has been approved to be
 patent Chinese herbal injection for marketing authorization by
hina Food and Drug Administration.7 A phase IV clinical trial has
een conducted to evaluate TRQ without control group, in which
ut of 2066 patients 166 children and 482 adults were diagnosed
s AB. The results showed that effective rates were 99.4% in chil-
ren and 99% in adults respectively. In addition, no severe adverse
eactions happened to all patients in this trial.8 Thus, TRQ is widely
sed in mainland China, and many clinical trials reported that TRQ
ould signiﬁcantly alleviate symptoms and improve signs.9,10
TRQ has been conﬁrmed to protect against inﬂuenza virus,
denovirus, syncytial virus, and coxsackie virus,11 and have good
nhibitory effect on streptococcus pneumoniae, staphylococcus .  . .  . . . .  . . .  . . . . .  .  . . . . .  . .  .  .  . . .  . . .  . . . . . . .  .  . . .  .  . . . .  .  .  . . . . .  . . . . . . .  .  .  .  . . .  .  . .  . . . .  .  157
aureus, beta hemolytic streptococcus, bloodthirsty bacillus ﬂu,
and legionella bacteria.12 So far, there have been two systematic
reviews and meta-analysis about TRQ for community acquired
pneumonia and acute exacerbations of chronic obstructive pul-
monary disease.9,10 However, no systematic review of randomized
controlled trials of TRQ for AB is published. Therefore, the aim of
this systematic review is to summarize and evaluate the evidence
on the efﬁcacy and safety of TRQ for AB.
2. Methods
2.1. Database and search strategies
The relevant studies were retrieved from the following
databases from their inception until October 2014: Medline,
EMBASE, Cochrane Library, Science Citation Index and four Chinese
databases, China National Knowledge Infrastructure (CNKI), Wan
Fang Database (WanFang), Chinese Biomedical Literature (CBM),
and Weipu Database for Chinese Technical Periodicals (VIP). The
following search terms were used individually or combined ‘Tan-
reqing’, ‘acute bronchitis’ and ‘randomized controlled trials’. The
bibliographies of included records were searched for additional
References.
2.2. Inclusion criteria
(1) All randomized controlled trials (RCTs) comparing TRQ
versus antibiotics drugs (antibitics drug including levoﬂoxacin,
azithromycin, amoxicillin, oxacillin sodium, cefuroxime, cefop-
erazone sulbactam, ceftazidime, cefepime cefaclor, ceftriaxone,
clavulanate potassium, cefoxitin, cefathiamidine, mezlocillin
baypen and penicillin), TRQ plus antiviral drugs versus
antiviral drugs (antivial drugs including ribavirin, potassium
sodium dehydroandroan drographolide succinate for injection
and vidarabine monophosphate), TRQ plus antibiotics versus
antibiotics, TRQ versus antibiotics plus antiviral drugs, TRQ
plus conventional therapy versus conventional therapy were
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reducing phlegm, relieving dyspnea, reducing fever, and other
symptomatic therapy.
2) Patients diagnosed as AB, whether adults or children, without
limitation in ages, gender and ethnicity were included.
3) The following outcomes were evaluated: primary outcomes:
effective rates13 (the effective rate was calculated based on
the proportion of participants with resolution or improvement
of symptoms. We converted the effective rate to dichotomous
data in meta-analyses), and time to resolution of symptoms like
fever, cough, crackles, and absorption of shadows on X-ray.
Secondary outcome: adverse drug reactions or events.
.3. Exclusion criteria
.3.1. Studies meeting the following items were excluded.
1) Non-clinical trials;
2) Data can not be extracted;
3) Duplicate publications;
4) Patients with other comorbidities;
5) Not administered by intravenous drip.
.4. Selection of studies
Two reviewers (WP  and LLH) independently selected trials
or inclusion criteria by scanning the title and abstract of each
ecord and retrieved their full-text if necessary. Any disagreement
etween two reviewers was solved by discussion with the third
arty (LX and XYM).
.5. Data extraction and management
Two reviewers (WP  and LLH) independently extracted data with
 pre-deﬁned data extraction form. Data on study characteristics
as extracted, including study design, participants, interventions,
utcomes and adverse drug reactions or events. Any disagreement
as discussed with a third party (LX and XYM) until a consensus
as reached.
.6. Assessment of risk of bias about the included studies
Two reviewers (WP  and LLH) independently assessed the risk
f bias for each study using the criteria outlined in the Cochrane
andbook for Systematic Reviews of Interventions (Version 5.1.0).
andom sequence generation (selection bias), allocation con-
ealment (selection bias), blinding of participants and personnel
performance bias), blinding of outcome assessment (detection
ias), incomplete outcome data (attrition bias), selective reporting
reporting bias) and other bias were taken into account for assess-
ent. The quality of all the included trials was categorized into low
isk, high risk or uncertain risk (“Yes” for a low risk of bias, “No”
or a high risk of bias, “Unclear” otherwise). Based on these criteria,
ach study could be divided into three grades as follows: low risk
f bias (low risk of bias for all key domains), unclear risk of bias
unclear risk of bias for one or more key domains), and high risk of
ias (high risk of bias for one or more key domains). Discrepancies
ere resolved by discussion between reviewers.
.7. Data synthesis
Review Manager software (Version 5.3) provided by the
ochrane Collaboration was used for data analysis. Dichotomous
ariable was presented as relative risk (RR). Continuous outcome
as presented as mean difference (MD) and its 95% CI. Statistical
eterogeneity was assessed according to the Cochrane Handbook
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heterogeneity was evaluated with I-squared (I2) statistic. If
there was  no signiﬁcant heterogeneity among the included trials
(I2 ≤ 50%), ﬁxed effects model was used, if not(I2 > 50%), ran-
dom effects model was  used. Subgroup analysis was conducted
according to the different types of interventions used in the trial.
Publication bias would be assessed by funnel plot, if the number of
studies were sufﬁcient.
2.8. Subgroup analysis
We had planned to perform the subgroup analysis on two types
of patients (adults and children) for all outcomes in this systematic
review. Patients with AB were divided into two groups (adults with
age ≥18; children with age <18).
2.9. Sensitivity analysis
Sensitivity analysis was performed by excluding those low qual-
ity trials or using different statistical methods (ﬁxed-effect and
random-effects models) to pool data.
3. Results
3.1. Description of included studies
After excluding duplicate publications by NoteExpress software,
a total of 124 potentially eligible records were identiﬁed. After
reading the titles and abstracts, a total of 45 trials with inappropri-
ate populations/interventions/administration, 17 nonrandomized
controlled trials, and 13 trials with incomplete data were excluded.
Finally, a total of 49 studies were included. Two trials provided
the average age of all participants, but did not report the respec-
tive number of children or adults. All the trials were published
in Chinese. The characteristics of the included trials are listed in
Table 1. The selecting process for included studies was presented
as following (Fig. 1).
3.2. Methodological quality
The methodological quality of included studies was assessed
by the criteria in the “Cochrane Handbook for Systematic Review
of interventions” (see Figs. 2 and 3). The methodological quality
of most studies was “poor”. Most of the included studies did not
report method of randomization. None of the studies mentioned
the methods of allocation concealment or blinding (patients, clini-
cians or outcome assessors). Only one study15 reported information
on follow-up of three to six months. The number of participants in
control group of two studies29,30 changed after treatment without
any explanation. One trial43 reported the improvement of extent
of symptoms, but the measurement was  different from others.
Selective reporting in other studies was  unclear due to the unavail-
ability of the research protocol. The sample size calculation was  not
reported by any of the included studies.
3.3. Effectiveness
3.3.1. TRQ versus antibiotics
Three trials32,52,62 reported clinical effective rates of TRQ versus
antibiotics. One meta-analysis showed that there was a signiﬁcant
difference between the two  groups (RR: 1.12; 95% CI = [1.05, 1.18];
P = 0.0002) and a signiﬁcant difference for children (RR: 1.12; 95%
CI = [1.05, 1.20]; P = 0.0005) (Fig. 4). However, there was no statisti-
cally signiﬁcant difference for adults. Only one trial52 reported the
improvement of symptoms, including time to resolution of fever,
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Table  1
Characteristics of the included studies.
Study ID Sample size (N) Mean age (x ± s, years) Diagnostic criteria Intervention Control Course (qd) Outcome measure
Kan14 N = 71 34.5 ± 2.5 NA TRQ + AB AB 7 ER
(T:35, C:36)
Chen15 N = 68 48.7 ± 10.3 TRQ + AB AB 5 1. ER 2. IT
(T:34, C:34)
Shen16 N = 56 T:36.5 ± 10.3 NA TRQ + AB AB 5 1. ER 2. IT
(T:28, C:28) C:35.7 ± 11.6
Li17 N = 88 T:35.5 ± 2.3 NA TRQ + CT CT 7 1. ER 2. IT
(T:44, C:44) C:34. 9 ± 3. 3
Niu and Zhang18 N = 68 48.7 ± 10.3 TRQ + AB AB 7 ER
(T:40, C:28)
Kong19 N = 40 NA NA TRQ + AB AB 7 1. ER 2. IT
NA
Liu20 N = 100 NA NA TRQ + AB AB 7 1. ER 2. IT
(T:50, C:50)
Shi21 N = 160 NA NA TRQ AB + AV 07-Sep 1. ER 2. IT
(T:80, C:80)
Zhou22 N = 87 NA TRQ + AB AB 05-Jul 1. ER 2. IT
(T:45, C:42)
Zhang23 N = 324 NA TRQ + AV AV 7 ER
(T:219, C:105)
Yang et al.24 N = 141 NA TRQ + AB AB 7 1. ER 2. SC
(T:70, C:71)
Jing25 N = 40 NA NA TRQ + AB AB 7 ER
NA
Ruan26 N = 60 NA TRQ + AB AB 7 1. ER 2. IT
(T:30, C:30)
Wu27 N = 120 NA NA TRQ + AB AB 7 1. SC 2. IR
(T:60, C:60)
Sun28 N = 80 T:37.08 ± 10.64 TRQ + CT CT 7 1. ER2. IT
(T:40, C:40) C:38. 63 ± 10. 62
Tang29 N = 172 NA NA TRQ + AB AB NA 1. ER 2. IT
(T:86, C:86)
Hu30 N = 78 NA TRQ + AB AB 7 1. ER 2. IT
(T:41, C:37)
Meng and Da31 N = 105 NA NA TRQ AB + AV 7 1. ER 2. IT
(T:60, C:55)
Liu32 N = 106 NA NA TRQ AB 07-Oct ER
NA
Ma33 N = 126 NA other TRQ + CT CT 7 1. ER 2. IT
(T:63, C:63)
Zhang34 N = 112 NA NA TRQ + AB AB 6 ER
(T:58, C:54)
Liu35 N = 50 NA other TRQ + AV AV 05-Jul ER
(T:25, C:25)
Cui36 N = 120 T:8.1 ± 2.7 other TRQ + AV AV 7 1. ER 2. IT
(T:60, C:60) C:8.0 ± 2.9
Xu et al.37 N = 80 NA TRQ + CT CT 7 ER
(T:40, C:40)
Yang38 N = 108 NA NA TRQ + AV AV 7 ER
NA
Zhang39 N = 116 NA TRQ + CT CT 7 1.ER 2. IT
(T:58, C:58)
Feng40 N = 81 NA NA TRQ + CT CT 7 1ER 2. IT
(T:41,  C:40)
Li41 N = 320 NA NA TRQ + CT CT 10 ER
(T:220, C:100)
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Zhou42 N = 78 NA NA TRQ + AB AB 7 ER
(T:46,  C:32)
Yang43 N = 53 NA NA TRQ AB + AV 07-Oct 1. ER 2. IT
(T:27, C:26)
Guan44 N = 80 NA NA TRQ + AV AV 7 ER
NA
Li45 N = 60 NA other TRQ + CT CT 7 1. ER 2. IT
(T:30, C:30)
Wu46 N = 122 NA TRQ + AB AB 7 1. ER 2. IT
(T:62, C:60)
Fang47 N = 90 NA TRQ + AV AV 05-Jul ER
(T:45, C:45)
Chen48 N = 80 NA other TRQ + CT CT 7 ER
(T:40, C:40)
Yang49 N = 60 NA other TRQ + AV AV 7 1. ER 2. IT
(T:30, C:30)
Hu et al.50 N = 120 NA NA TRQ + AB AB 7 ER
(T:75, C:45)
Zhang et al.51 N = 72 NA NA TRQ + AB AB 5 1. ER 2. SC
(T:35, C:37)
Yuan et al.52 N = 205 NA NA TRQ AB 05-Jul ER
(T:116, C:89)
Guo and Du53 N = 84 NA NA TRQ AB + AV 07-Oct 1. ER 2. IT
(T:42, C:42)
Feng54 N = 84 NA NA TRQ AB + AV 07-Oct 1. ER 2. IT
(T:42, C:42)
Yang55 N = 72 T:45 ± 4 TRQ + AB AB 07-Oct 1. ER2. IT
(T:36, C:36) C:44 ± 5
Yang56 N = 66 NA NA TRQ + AB AB 7 1. ER2. WBC
(T:36, C:30)
Zhang57 N = 210 54.32 ± 12.34 other TRQ + AB AB 7 1. ER2. TNF-a
NA
Chang58 N = 116 NA TRQ + AV AV 7 1. ER 2. IT
(T:62, C:54)
Zhang59 N = 83 NA NA TRQ + AB AB 5 ER
(T:41, C:42)
Niu and Xu60 N = 63 NA NA TRQ + AB AB 5 ER
(T:38, C:25)
Tian and Shen61 N = 120 T:65 ± 4 NA TRQ + AB AB 05-Oct ER
(T:60, C:60) C:64 ± 5
An et al.62 N = 136 NA TRQ AB 7 1. ER 2. SC
(T:68, C:66)















−0.86]; P < 0.00001).ote: T = Tanreqing group; C = control group; AB = antibiotics; AV = antiviral drugs; C
n  new drugs of Chinese medicine; = practice of internal medicine; = textb
ymptom; SC = symptom score results; IR = comprehensive clinical improvement ra
ough, and crackles. It showed that TRQ group was better than
ntibiotics group.
.3.2. TRQ plus conventional therapy versus conventional therapy
Nine trials17,28,33,37,39–41,45,48 reported clinical effective rates
f TRQ plus conventional therapy versus conventional ther-
py. Meta analysis showed that there was a signiﬁcant dif-
erence between the two groups (RR: 1.21; 95% CI = [1.15,
.27]; P < 0.00001) (Fig. 5). In children,33,37,39–41,45,48 the results
howed more beneﬁt in experimental group compared to
ontrol group (RR: 1.20; 95% CI = [1.14, 1.27]; P < 0.00001). As for
he adults,17,28 the results showed that experimental group had
ore beneﬁcial effects than control group (RR = 1.23; 95% CI = [1.10,
.38]; P = 0.0004).nventional therapy; NA = not applicable; = guiding principle of clinical research
 pediatrics; = internal medicine; ER = effective rates; IT = improvement time of
BC  = the number of white blood cells.
Seven studies17,28,33,37,39,40,45 reported time to fever resolu-
tion. Meta-analysis showed a signiﬁcant beneﬁcial effect of TRQ
compared to conventional therapy in improving the time to fever
resolution (MD: −1.06; 95% CI = [−1.13, −0.98]; P < 0.00001) (Fig. 6).
For children,33,37,39,40,45 the results showed a signiﬁcant improve-
ment of fever resolution in experimental group compared to control
group (MD: −1.05; 95% CI = [−1.13, −0.97]; P < 0.00001). As for the
adults,17,28 the results showed that experimental group had more
beneﬁcial effects than control group (MD: −1.14; 95% CI = [−1.43,Seven studies17,28,33,37,39,40,45 reported reduction of cough.
Meta-analysis showed effect of experimental group was supe-
rior to conventional group in improving the reduction of cough
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fFig. 2. Risk of bias graph of r
MD: −1. 84, 95% CI = [−2.85, −0.83], P = 0.0003) (Fig. 7). For
33,37,39,40,45hildren, the results showed a signiﬁcant improvement
f cough resolution in experimental group compared to con-
rol group (MD: −1.85; 95% CI = [−3.09, −0.61]; P = 0.003). But
or adults,17,28 the results showed that the difference betweenized controlled trials on AB.
experimental and control group was not statistically signiﬁcant
(MD  = −1.85; 95% CI = [−4.27, 0.63]; P = 0.14).
Two studies37,40 reported the duration for crackle (MD  = −1.56;
95% CI = [−2.28, −0.85]; P < 0.0001), one study40 reported the
absorption of chest X-ray shadow (MD  = −1.30; 95% CI = [−2.19,
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Fig. 3. Risk of bias summary of randomized controlled trials on AB.
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rFig. 5. TRQ plus conventional therapy ve
0.41]; P = 0.004), showing that experimental group was better
han control group.
.3.3. TRQ plus antibiotics versus antibiotics
A total of 24 trials14–16,18–20,22,24–27,29,30,34,42,46,50,51,55–57,59–61
eported clinical effective rates of TRQ plus antibiotics versus
ntibiotics. Meta analysis showed that there was a signiﬁcant dif-
erence between the two groups (RR: 3.46; 95% CI = [2.59, 4.62];
 < 0.00001) (Fig. 8). In children,19,22,25,27,29,60 the results showed
ore beneﬁt in experimental group compared to control group (RR:
.24; 95% CI = [1.33, 7.86]; P = 0.009). As for the adults, the results of
ighteen trials14–16,18,20,24,26,30,34,42,46,50,51,55–57,59,61 showed that
xperimental group was better than control group (RR: 3.82; 95%
I = [2.75, 5.31]; P < 0.00001).
Seven trials15,16,18,26,30,46,55 about adults reported the time to
ever resolution. Meta-analysis showed a signiﬁcant beneﬁcial
ffect of experimental group compared to control group in reducing
he time to fever resolution. (MD: −1.33; 95% CI = [−1.81, −0.86];
 < 0.00001) (Fig. 9).
Seven trials15,16,18,26,30,46,55 reported the reduction of cough. The
esults showed a signiﬁcant improvement of reduction of coughonventional therapy: the effective rates.
in experimental group compared to control group in adults (MD:
−2.65; 95% CI = [−2.88, −2.42]; P < 0.00001) (Fig. 10).
Four trials15,16,30,46 reported the duration for crackles and
absorption of chest X-ray shadow. Meta-analysis (MD: −2.09; 95%
CI = [−2.82, −1.36]; P < 0.00001) about the duration of crackles and
(MD: −1.75; 95% CI = [−2.42, −1.09]; P < 0.00001) about the absorp-
tion of chest X-ray shadow were conducted. The results showed
signiﬁcant beneﬁcial effects of experimental group compared with
control group.
3.3.4. TRQ versus antibiotics plus antiviral drugs
Five trials21,31,43,53,54 reported clinical effective rates of TRQ
group versus antibiotics plus antiviral drugs group in treatment for
children. Meta analysis showed that there was a signiﬁcant differ-
ence between the two  groups (RR: 2.03; 95% CI = [1.10, 3.74]; P = 0.
02) (Fig. 11). It showed that experimental group was  better than
antibiotics group.Five trials21,31,43,53,54 reported the time to fever resolution. A
random-effect model was used and meta-analysis showed that
experimental group had more beneﬁt compared with control group
(MD: −0.88; 95% CI = [−1.25, −0.51]; P < 0.00001) (Fig. 12).
P. Wang et al. / Complementary Therapies in Medicine 25 (2016) 143–158 151








aFig. 7. TRQ plus conventional therapy ve
These trials also reported the reduction of cough. Meta-analysis
howed that experimental group had more beneﬁt compared with
ontrol group. (MD: −1. 63; 95% CI = [−1.89, −1.36]; P < 0.00001)
Fig. 13).
Four trials21,43,53,54 reported duration of crackles and absorption
f chest X-ray shadow. Meta-analysis (MD: −1. 26; 95% CI = [−1.87,
0.64]; P < 0.00001) (Fig. 14) about the duration of crackles and
MD: −0.52; 95% CI = [−0.93, −0.11]; P = 0.01) (Fig. 15) about the
bsorption of chest X-ray shadow were conducted. The resultsnventional therapy: reduction of cough.
showed signiﬁcant beneﬁcial effects of experimental group com-
pared with control group.
3.3.5. TRQ plus antiviral drugs versus antiviral drugs
A total of eight trials23,35,36,38,44,47,49,58 reported clinical effec-
tive rates of TRQ plus antiviral drugs versus antiviral drugs. Meta
analysis showed that there was  a signiﬁcant difference between
the two groups (RR: 5.12; 95% CI = [3.03, 8.66]; P < 0.00001) and a
signiﬁcant difference for children (RR: 5.30; 95% CI = [3.05, 9.20];
P < 0.00001) (Fig. 16).
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Fig. 8. TRQ plus antibiotics versus antibiotics: the effective rates.
Fig. 9. TRQ plus antibiotics versus antibiotics: time to fever resolution.
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aFig. 11. TRQ group versus antibiotic
Three trials36,49,58 reported the time to reduction of fever and
ough. Meta-analysis showed a signiﬁcant beneﬁcial effect of
xperimental group than control group in reducing the time to
ever resolution (MD: −1.08; 95% CI = [−1.59, −0.57]; P < 0.00001)
Fig. 17). Meta-analysis showed a signiﬁcant beneﬁcial effect of TRQ
roup than control group in improving the cough duration (MD:
2.27; 95% CI = [−3.11, −1.43]; P < 0.00001) (Fig. 18). Only one study
36] reported the duration of crackles, showing that TRQ group was
etter than antiviral drugs group.
.4. Adverse drug reactions/events
Out of 49 included trials four trials15,17,23,29 reported adverse
eactions (mild skin rash, infusion reaction, hypersensitiveness and
ausea). In TRQ group, one patient with pruritus and two  patients
ith rash were reported. In control group, eleven patients with
llergy reactions were reported. After proper medical treatment, antiviral drugs: the effective rates.
all patients experiencing adverse drug reactions completely recov-
ered.
3.5. Publication bias
A simple analysis of funnel plots provides a useful test for the
likely presence of bias in meta-analysis. The results about effective
rates of this systematic review showed that the funnel plot was
asymmetrical. It indicated that there was publication bias (Fig. 19).
4. Discussion
4.1. Statement the systematic reviewThe diagnosis of Acute Bronchitis (AB) should be based on
clinical symptoms and signs assessment since there is no gold
standard test.63 Patients suffering from a respiratory illness with
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Fig. 12. TRQ versus antibiotics plus antiviral drugs: time to fever resolution.






eFig. 14. TRQ versus antibiotics pl
roductive cough and fever and patients with other comorbidities
ere excluded. The clinical characteristics of the patients included
ere consistent with the variety of similar deﬁnitions generally
sed by clinicians. Therefore, these results would appear to be gen-
ral ability to the management of AB in practices.iviral drugs: duration of crackles.
AB is traditionally treated with antibiotics. But evidence for the
effectiveness of antibiotics over placebo is only modest.64 Chinese
medicinal herbs have also been used as a treatment for treating
patients with AB.65 traditional Chinese medicine has long been
used to treat acute cough illnesses and other respiratory tract infec-
tions in China, and some are thought to have antibacterial and
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wFig. 16. TRQ plus antiviral drugs v
ntiviral properties.66 Tanreqing injection (TRQ) is a compound
reparation with marked curative effect on the diseases of upper
espiratory tract infection, as the ﬁrst new drug for the quality con-
rol through ﬁngerprint, and is widely used in China.67 The main
ctive pharmaceutical ingredients include: chlorogenic acid, caffeic
cid, luteoloside, forsythiaside, forsythin, forsythigenol, baicalin,
ogonoside, wogonin, ursodeoxycholic acid, chenodeoxycholic
cid, and salidroside.68 The treatment course of intravenous drip-
ing TRQ is 7 days. The routine dose is from 20 ml  to 40 ml  for adults
nd the total dose is less than 20 ml,  calculated according to body
eight, for children, once daily.ntiviral drugs: the effective rates.
To date, there has been no systematic review to evaluate efﬁ-
cacy and safety of TRQ injection in the treatment of acute bronchitis.
Therefore, a total of 49 trials with 5131 participants were analyzed.
Patients with AB were performed into three subgroups (children
group with age <18, adults group adults with age ≥18 and all age
group) to evaluate effectiveness and safety of TRQ. Since children
and adults may  have different reactions to the treatment, we per-
formed subgroup analysis to explore the differences. The results
reported the proportion of patients with improved signs showed
that TRQ were beneﬁcial for the relief of signs and symptoms. On the
basis of the available trials data TRQ can be considered as effective
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Fig. 17. TRQ plus antiviral drugs versus antiviral drugs: time to fever resolution.
Fig. 18. TRQ plus antiviral drugs versus antiviral drugs: reduction of cough.





















































injection plus cefoperazone sulbactam. World Health Digest.  2013;(31):61–62.
24. Yang HW,  A BLZ, You CX. Clinical observation on 70 cases of acute bronchitisP. Wang et al. / Complementary Th
or symptom resolution of acute bronchitis in adults and in children.
ll patients in group of TRQ versus antibiotics plus antiviral drugs
re children. We  may  consider that TRQ treatment for children has
ore advantages than the treatment for adults. Subgroup analysis
lso revealed that TRQ combined with western medicine (antibi-
tics or antiviral therapies) appeared to be more effective than
estern medicine alone. The composition of TRQ like chlorogenic
cid, baicalin, forsythin, ursodeoxycholic acid may  cause adverse
rug reaction.69 TRQ could cause allergic reactions, including dizzi-
ess, nausea, vomiting, visible body redness, itching and rash. In
his review, adverse drug reactions of TRQ possibly include rash and
tching. Although no serious adverse drug reactions were found in
his systematic review, TRQ is extracted from ﬁve kinds of Chinese
edicines including two materials (bear gall powder and cornu
orais) from animals. The main components in Bear gall powder
re bile acid and metal salts, which could be a high risk factor for
llergy reaction.70 There are several methods to deal with ADRs.
irstly, syndrome differentation diagnosis should be made accord-
ng to traditional Chinese medicine theories. Since components of
RQ contained belongs to Chinese medicine materials with cold
uality, it was mainly used for heat syndrome68,71; secondly, allergy
uffer should be treated carefully because TRQ contained allergy
ausing substances69; thirdly, it is should be administered by intra-
enous dripping, avoiding being mixed with other drugs in the
ame bottle.72
AMSTAR73 and PRISMA checklists74 were used to assess this
ystematic review for the sake of quality control and rigor.
.2. Limitations of this systematic review
Most of the trials were with poor methodology according to
ochrane Handbook for Systematic Reviews of Interventions (Ver-
ion 5.1.0). All the included trials mentioned randomization, while
he method about randomization were rarely described. Alloca-
ion concealment and blind method were also not mentioned. Only
ne study33 mentioned using random number table. Selection bias
ould exist due to lack of reporting random sequence generation
nd allocation concealment. It was prone to generate measure-
ent bias without blinding method. All trials did not mention the
ethods of statistical analysis.
Eight English and Chinese electronic databases were searched,
ut all the 49 trials were published in Chinese. Publication bias
xisted.
The sample size of 29 trials14–20,22,25,26,28,30,35,37,40,42–45,47–49,51,53
ere quite small, varied from 40 to 100 patients. It could lead to
xaggerated or weakened results.
. Conclusion
This systematic review is the ﬁrst one that assessed the efﬁcacy
nd safety of TRQ injection in the treatment of acute bronchitis. And
ata was pooled and analyzed for adults and children respectively.
t is hoped to imply the future clinical practice. However, we  could
ot make a conﬁdent conclusion due to poor quality of the included
tudies. There is a need for large-scale, strictly designing, trials in
uture.
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